N-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-N-methylpropanamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-N-methylpropanamide
• 化学式: C₁₃H₁₃ClN₂OS
• 分子量: 280.77
• InChiKey: YUFHGJMUVWQPMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  61.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  丙酰氯 生成 N-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-N-methylpropanamide
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Thiazole Derivatives as Alpha 7 NACHR Modulators
  申请人：LUPIN LIMITED

  公开号：US20150299178A1

  公开（公告）日：2015-10-22

  Disclosed is a compound of formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 and m are as described herein, as a modulator of nicotinic acetylcholine receptors particularly α7 subtype, its tautomeric forms, its stereoisomers, its pharmaceutically acceptable salts, its pharmaceutical composition, and its combinations with suitable medicaments. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.

  公开了一种化合物的式子(I)，其中R1、R2、R3、R4、R5和m如此描述，作为尼古丁乙酰胆碱受体特别是α7亚型的调节剂，其互变异构体，其立体异构体，其药学上可接受的盐，其药物组合物，以及其与适当药物的组合物。还公开了一种制备该化合物的方法以及在治疗中的预期用途，特别是在防治阿尔茨海默病、轻度认知障碍、老年性痴呆等疾病中。
• ——
  作者：LANGE A.、 WUERZER B.、 MEYER N.

  DOI：——

  日期：——
• THIAZOLE DERIVATIVES AS ALPHA 7 NACHR MODULATORS
  申请人：Lupin Limited

  公开号：EP2945936A1

  公开（公告）日：2015-11-25
• [EN] THIAZOLE DERIVATIVES AS ALPHA 7 NACHR MODULATORS<br/>[FR] DÉRIVÉS DE THIAZOLE EN TANT QUE MODULATEURS DE NACHR ALPHA-7
  申请人：LUPIN LTD

  公开号：WO2014072957A1

  公开（公告）日：2014-05-15

  Disclosed is a compound of formula (I), wherein R1, R2, R3, R4, R5 and m are as described herein, as a modulator of nicotinic acetylcholine receptors particularly α7 subtype, its tautomeric forms, its stereoisomers, its pharmaceutically acceptable salts, its pharmaceutical composition, and its combinations with suitable medicaments. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.